白细胞滤除联合病原体减少技术在犬输血模型中预防同种免疫性血小板输注无效
在犬血小板输注模型中,供受者犬淋巴细胞抗原DR-B不相合占88%,受者每周接受单供者处理血小板输注。白细胞滤除联合Mirasol病原体减少(F-LR+MPR)使31/32(97%)受者接受输注,21/22(95%)接受后续未处理供者血小板,且无一产生供者淋巴细胞抗体。
要点
- F-LR+MPR血小板被21/22(95%)受者接受,显著高于F-LR+γ-I的2/10(20%)(P < .001)。
- F-LR+MPR接受者中7/21(33%)对后续8次未处理供者血小板产生特异性耐受。
- F-LR+MPR全血制备的血小板浓缩物10/10(100%)受者接受,无一产生供者淋巴细胞抗体。
核心结论
- F-LR+MPR在犬模型中实现了97%(31/32)的血小板输注接受率,为动物或人类中报道的最高接受率。
- 该方法可能对免疫系统完整的患者(如骨髓增生异常综合征)支持治疗尤为重要。
研究设计与样本
- 犬血小板输注模型研究,供受者犬淋巴细胞抗原DR-B不相合对占88%。
- 受者接受最多8次每周单供者处理血小板输注(强免疫原刺激),或直至血小板输注无效。
主要发现
- F-LR血小板持续被接受者6/13(46%);γ-I组0/5;MPR组1/7。
- F-LR+γ-I组接受者2/10(20%);F-LR+MPR组接受者21/22(95%),与F-LR+γ-I组比较P < .001。
- F-LR+MPR接受者中7/21(33%)对后续8次未处理供者血小板产生特异性耐受。
- F-LR+MPR全血制备的血小板浓缩物被10/10(100%)受者接受。
- 总体31/32(97%)受者接受F-LR+MPR血小板,无一产生供者淋巴细胞抗体。
关键数值与推荐
- F-LR+MPR组接受率21/22(95%)vs F-LR+γ-I组2/10(20%),P < .001。
- F-LR组接受率6/13(46%);γ-I组0/5;MPR组1/7。
- F-LR+MPR全血制备血小板浓缩物接受率10/10(100%)。
- 总体F-LR+MPR接受率31/32(97%),供者淋巴细胞抗体发生率为0。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human lymphocyte antigen alloimmunization to filter leukoreduced (F-LR) platelets occurs in about 18% of immunosuppressed thrombocytopenic hematology/oncology patients and represents a significant challenge for effective chemotherapy. In a dog platelet transfusion model, we have evaluated other methods of preventing alloimmune platelet refractoriness and demonstrated that successful methods in our dog model are transferable to man. In the present study, donor/recipient pairs were dog lymphocyte antigen DR-B incompatible (88% of the pairs), and recipient dogs received up to 8 weekly treated transfusions from a single donor (a highly immunogenic stimulus), or until platelet refractoriness. Continued acceptance of F-LR platelets occurred in 6 of 13 recipients (46%), but neither γ-irradiation (γ-I; 0 of 5) nor Mirasol pathogen reduction (MPR; 1 of 7) treatment of donor platelets prevented alloimmune platelet refractoriness. Combining γ-I with F-LR was associated with only 2 of 10 (20%) recipients accepting the transfused platelets. Surprisingly, F-LR platelets that then underwent MPR were accepted by 21 of 22 (95%) recipients (P < .001 vs F-LR + γ-I recipients). Furthermore, 7 of 21 (33%) of these accepting recipients demonstrated specific tolerance to 8 more weekly donor transfusions that had not been treated. In addition, platelet concentrates prepared from F-LR + MPR whole blood were also nonimmunogenic; that is, 10 of 10 (100%) recipients accepted donor platelets. Overall, 31 of 32 (97%) recipients accepted F-LR + MPR platelets; none developed antibodies to donor lymphocytes. These data are the highest rate of acceptance for platelet transfusions reported in either animals or man. This approach to platelet transfusion may be particularly important when supporting patients with intact immune systems, such as in myelodysplastic syndromes.
引用
- Slichter SJ, Pellham E, Bailey SL, et al. Leukofiltration plus pathogen reduction prevents alloimmune platelet refractoriness in a dog transfusion model. Blood. 2017. PMID: 28705838. doi:10.1182/blood-2016-07-726901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。